A Clinical Prediction Tool for Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Urinary Tract Infection

Hui Liu  
Department of Pharmacy, The First Affiliated Hospital of Jinan University

Suishan Qiu  
Department of Pharmacy, The First Affiliated Hospital of Jinan University

Minghao Chen  
Department of Pharmacy, The First Affiliated Hospital of Jinan University

Jun Iyu  
Department of Clinical Research, The First Affiliated Hospital of Jinan University

Guangchao Yu  
Department of Laboratory Medicine, The First Affiliated Hospital of Jinan University

Lianfang Xue  (✉ xlf18666@163.com)  
Department of Pharmacy, The First Affiliated Hospital of Jinan University

Research Article

Keywords: extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE), ESBL-PE, empirical treatment

DOI: https://doi.org/10.21203/rs.3.rs-517907/v1

License: Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background
To explore the risk factors of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) infection through urine samples of hospitalized patients and establish a predictive model to improve treatment outcomes.

Methods
This retrospective study included all patients with an Enterobacteriaceae-positive urine sample at the first affiliated hospital of Jinan University from January 2018 to December 2019. Antimicrobial susceptibility patterns of ESBL-PE were analyzed, and multivariate analysis of related factors was performed. From these, a nomogram was established to predict the possibility of ESBL-PE infection. Simultaneously, susceptibility testing of a broad array of carbapenem antibiotics was performed on ESBL-PE cultures to explore possible alternative treatment options.

Results
Of the total 874 patients with urinary tract infections (UTIs), 272 (31.1%) were ESBL-PE positive. In the predictive analysis, five variables were identified as independent risk factors for ESBL-PE infection: male gender (OR=1.607, 95% CI 1.066-2.416), older age (OR=4.100, 95% CI 1.678-12.343), a hospital stay in preceding 3 months (OR=1.872, 95% CI 1.141-3.067), invasive urological procedure (OR=1.810, 95% CI 1.197-2.729), and antibiotic use within the previous 3 months (OR 0.546, 95% CI 0.314-0.948). In multivariate analysis, the data set was divided into a training set of 611 patients and a validation set of 263 patients. The model developed to predict ESBL-PE infection was effective, with the AuROC of 0.650 (95% CI 0.577-0.725). Among the antibiotics tested, several showed very high effectiveness against ESBL-PE: amikacin (85.7%), carbapenems (83.8%), tigecycline (97.1%) and polymyxin (98.2%).

Conclusions
The nomogram is useful for estimating a bacteremic patient’s likelihood of infection with ESBL-PE. It could improve clinical decision making and enable more efficient empirical treatment. Empirical treatment may be informed by the results of the antibiotic susceptibility testing.

Background
Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-PE) are a diverse family of Gram-negative bacteria, mainly Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae), which express a clinically concerning drug resistance mechanism [1]. ESBL-PE can hydrolyze and eliminate most broad-spectrum β-lactam antibiotics. Compared with non-ESBL-PE infections, serious infections caused by ESBL-PE have higher morbidity and mortality, and outbreaks are more difficult to control with current methods [2].
ESBL-PE hydrolysis of carbapenem antibiotics is low, so carbapenem antibiotics are often used as the first choice in clinical treatment of ESBL-PE infections. However, the abuse of carbapenems may result in the selection of carbapenem resistant Enterobacteriaceae, which will ultimately make it more difficult to treat this kind of bacteria [3, 4].

Several studies have suggested that infections caused by ESBL-PE have an important clinical impact, and the growing prevalence of these microorganisms in hospitals had been well proven [2, 4]. Urinary tract infections (UTIs) are the main type of bacterial infection in hospitalized patients, and many of these exhibit resistance to the first-line antibiotics usually used to treat UTIs. Infections caused by ESBL-PE were almost all nosocomial infections [5]. Patients who are identified to be at risk of ESBL-PE infection can have their treatment empirically tailored to reduce treatment failure, complications, and antibiotic costs, and to avoid improper use of carbapenem drugs, reducing the risk of selecting drug-resistant microorganisms [6].

A key component of managing ESBL-PE infection is to predict its incidence. A highly accurate predictive model can help identify high-risk patients and prevent or reduce the incidence of ESBL-PE infection. However, neither test indicators nor imaging tests can yet predict ESBL-PE infection. Therefore, this study aims to determine the prevalence and risk factors of ESBL-PE infection in hospitalized patients with urinary tract infections and to establish a reliable predictive model.

**Methods**

**Study Population**

This study was conducted at a university-affiliated tertiary hospital with 1900 beds. This study was conducted at the first affiliated hospital of Jinan university, a university-affiliated tertiary hospital in Guangzhou, China with 1900 beds. All cases from January 2018 to December 2019 in which all of a patient’s urine cultures tested positive for Enterobacteriaceae were reviewed. All non-repetitive mid-stream urine (MSU) samples obtained during the study period with a positive urine culture of either *E. coli* or *K. Pneumoniae* were included in the analysis. UTIs were defined in accordance with uniform diagnostic criteria of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [7]. Patients were excluded from the study if their medical records were missing data or if one or more of their samples were multi-microorganismal – defined as containing two or more pathogenic species in the same urine culture medium.

**Data collection and definitions of variables**

To identify predictors of urinary tract infections caused by ESBL-PE, we referred to previously reported studies on risk factors related to multidrug resistance, including ESBL. Demographic and clinical data were obtained from medical records. The collected variables included age, gender, comorbid diseases, hospital admission history, undergoing an invasive urological procedure (such as intubation or catheterization), treatment history, and antibiotic use in the past 3 months. Comorbid diseases included
chronic diabetes mellitus, chronic renal failure, immunodeficiency, neoplasia, recurrent UTIs, and severe underlying disease. Hospital admission history included such items as admission times, hospital stays in preceding 3 months, and admission history to the medical department, surgical department, or ICU.

**Susceptibility testing**

The drug susceptibility test used the paper diffusion method in accordance with the Clinical Laboratory Standards Institute (CLSI). The minimum inhibitory concentration (MIC) was passed through the Vitek 2 automated microbial identification system (Vitek AMS; bioMerieux Vitek Systems Inc., Hazelwood, Missouri). All results met the CLSI Enterobacteriaceae standards. Six types of antibacterial agents were tested: β-lactam/β-lactam Enzyme inhibitor combination (cefoperazone-sulbactam, piperacillin-tazobactam), cephalexin (ceftazolin, cefotaxime, ceftazidime, ceftriaxone, cefepime), carbapenem (imipenem, meropenem), aminoglycoside (amikacin), folate pathway inhibitor (trimethoprim-sulfamethoxazole), and fluoroquinolone (Levofloxacin) (Sigma-Aldrich, St. Louis, Missouri). Quality control was performed on *E. coli* (ATCC 25922) and *K. pneumoniae* (ATCC 700603) [8].

**Statistical analysis**

As age and admission times are continuous variables with non-normal distribution, both were grouped into categories (0-18 years, 18-60 years, 60+ years); thus, all data existed in the form of categorical variables. Internal verification was carried out using a resampling-based method. The data set was divided into two groups; 611 patients (70% of the study) were randomly selected as the training set, and 263 patients (the other 30%) were selected as the validation set. Pearson's chi-square test or Fisher's exact test was used to compare differences between data sets, as appropriate, and for univariate analysis in the training set. All variables with a P value less than 0.1 in the univariate analysis were input into the multivariate analysis to further select the variables in the predictive model.

A predictive model was established by applying multivariate logistic regression with variables selected from multivariate analysis. The risk predictive model of ESBL-PE infection was presented using a nomogram. The predictive model was evaluated on three criteria: discriminatory capacity, calibration ability, and clinical effectiveness. The AuROC was used to evaluate discriminative ability. The calibration curve and Hosmer-Lemeshow test were used to evaluate its calibration ability. Decision curve analysis (DCA) was used to evaluate clinical efficacy. All tests were two-tailed, and a P value of less than 0.05 was considered statistically significant. All statistical analyses were performed using R software (version 3.6.3, Vienna, Austria).

**Results**

**Demographics and clinical characteristics**

Figure 1 shows the overall experimental flow. The organisms of interest, *E. coli* and *K. pneumoniae*, were identified in urine cultures from 885 unique patients during the study period. Of these, 11 were removed
from the dataset: 9 cases were missing data, and 2 cases were identified to contain 2 pathogenic species. Table 1 shows a comparison of the demographic and clinical factors between the ESBL-PE and non-ESBL-PE patients. The median (IQR) ages at presentation were 65.5 (52-76) years for the ESBL-PE group and 61 (49-74) years for the non-ESBL-PE group ($P<0.001$). The proportions of ESBL-PE infections among males and females were 33.5% and 66.5%, respectively ($P=0.05$). The two groups were compared across numerous factors: several comorbid diseases, hospital admission history, invasive urological procedure treatment history, and antibiotic use in the past 3 months. Those which showed significant differences ($P<0.05$) were: diabetes mellitus, severe underlying disease, a hospital stay in the preceding 3 months, prior admission to the medical department, prior admission to the surgical department, prior admission to the ICU, undergoing an invasive urological procedure, and antibiotic use in the past 3 months. Among microorganisms, $E. \text{ coli}$ (739 cases, 84.6%) was the most commonly isolated species, with $K. \text{ pneumoniae}$ (135 cases, 15.4%) comprising the remainder.

Table 1. Demographic data, clinical characteristics
| Variables                                      | Overall (n=874) | Non-ESBL-PE (n=602) | ESBL-PE (n=272) | P value |
|------------------------------------------------|-----------------|---------------------|-----------------|---------|
| Gender, n (%)                                  |                 |                     |                 | 0.050   |
| Male                                           | 236 (27.0)      | 145 (24.1)          | 91 (33.5)       |         |
| Female                                         | 638 (73.0)      | 457 (75.9)          | 181 (66.5)      |         |
| Age (years), [median (IQR)]                    | 62.0 (50-75)    | 61 (49-74)          | 65.5 (52-76)    | <0.001  |
| Comorbidity diseases                           |                 |                     |                 |         |
| Diabetes mellitus, n (%)                       |                 |                     |                 | 0.038   |
| Yes                                            | 287 (32.8)      | 211 (35.0)          | 76 (27.9)       |         |
| No                                             | 587 (67.2)      | 391 (65.0)          | 196 (72.1)      |         |
| Chronic renal failure, n (%)                   |                 |                     |                 | 0.208   |
| Yes                                            | 123 (14.1)      | 91 (15.1)           | 32 (11.8)       |         |
| No                                             | 751 (85.9)      | 511 (84.9)          | 240 (88.2)      |         |
| Immunodeficiency, n (%)                        |                 |                     |                 | 0.056   |
| Yes                                            | 51 (5.8)        | 29 (4.8)            | 22 (8.1)        |         |
| No                                             | 823 (94.2)      | 573 (95.2)          | 250 (91.9)      |         |
| Neoplasia, n (%)                               |                 |                     |                 | 0.072   |
| Yes                                            | 103 (11.8)      | 63 (10.5)           | 40 (14.7)       |         |
| No                                             | 771 (88.2)      | 539 (89.5)          | 232 (85.3)      |         |
| Recurrent Urinary tract infections, n (%)      |                 |                     |                 | <0.001  |
| Yes                                            | 134 (15.3)      | 66 (11.0)           | 68 (25.0)       |         |
| No                                             | 740 (84.7)      | 536 (89.0)          | 204 (75.0)      |         |
| Severe underlying disease, n (%)               |                 |                     |                 | 0.009   |
| Yes                                            | 66 (7.6)        | 36 (6.0)            | 30 (11.0)       |         |
| No                                             | 808 (92.4)      | 566 (94.0)          | 242 (89.0)      |         |
| Hospital stay in preceding 3 months, n (%)    |                 |                     |                 | <0.001  |
| Yes                                            | 309 (35.4)      | 168 (27.9)          | 141 (51.8)      |         |
| No                                             | 565 (64.6)      | 434 (72.1)          | 131 (48.2)      |         |
| Previous hospitalization department            |                 |                     |                 |         |
Following random sampling, 611 patients, including 191 (31.3%) ESBL-PE patients, were included in the training set. The remaining 263 patients, with 82 (31.2%) ESBL-PE patients, were assigned to the validation set. No significant difference in the variables was observed between the training validation sets (all $P > 0.05$), as shown in Table 2.

Table 2. Clinical features and risk factor exposition in the study population.
| Variables                                      | Overall (n=874) | Training set (n=611) | Validation set (n = 263) | P value |
|------------------------------------------------|-----------------|----------------------|--------------------------|---------|
| Status, n (%)                                  |                 |                      |                          | 0.981   |
| ESBL-                                          | 602 (68.9)      | 420 (68.7)           | 181 (68.8)               |         |
| ESBL+                                          | 272 (31.1)      | 191 (31.3)           | 82 (31.2)                |         |
| Gender, n (%)                                  |                 |                      |                          | 0.111   |
| Male                                           | 236 (27.0)      | 176 (28.8)           | 62 (23.6)                |         |
| Female                                         | 638 (73.0)      | 435 (71.2)           | 201 (76.4)               |         |
| Age, n (%)                                     |                 |                      |                          | 0.543   |
| 0 to 18 years                                  | 70 (8.0)        | 49 (8.0)             | 21 (8.0)                 |         |
| 18 to 60 years                                 | 309 (35.4)      | 209 (34.2)           | 100 (38.0)               |         |
| Over 60 years                                  | 495 (56.6)      | 353 (57.8)           | 142 (54.0)               |         |
| Comorbidity diseases                           |                 |                      |                          |         |
| Diabetes mellitus, n (%)                       |                 |                      |                          | 0.920   |
| Yes                                            | 287 (32.8)      | 200 (32.7)           | 87 (33.1)                |         |
| No                                             | 587 (67.2)      | 411 (67.3)           | 176 (66.9)               |         |
| Chronic renal failure, n (%)                   |                 |                      |                          | 0.998   |
| Yes                                            | 123 (14.1)      | 86 (14.1)            | 37 (14.1)                |         |
| No                                             | 751 (85.9)      | 525 (85.9)           | 226 (85.9)               |         |
| Immunodeficiency, n (%)                        |                 |                      |                          | 0.913   |
| Yes                                            | 51 (5.8)        | 36 (5.9)             | 15 (5.7)                 |         |
| No                                             | 823 (94.2)      | 575 (94.1)           | 248 (94.3)               |         |
| Neoplasia, n (%)                               |                 |                      |                          | 0.170   |
| Yes                                            | 103 (11.8)      | 78 (12.8)            | 25 (9.5)                 |         |
| No                                             | 771 (88.2)      | 533 (87.2)           | 238 (90.5)               |         |
| Recurrent Urinary tract infections, n (%)      |                 |                      |                          | 0.496   |
| Yes                                            | 134 (15.3)      | 97 (15.9)            | 37 (14.1)                |         |
| No                                             | 740 (84.7)      | 514 (84.1)           | 226 (85.9)               |         |
| Severe underlying disease, n (%)               |                 |                      |                          | 0.056   |
|                         | Yes       | 66 (7.6) | 53 (8.7) | 13 (4.9) |
|-------------------------|-----------|----------|----------|----------|
|                         | No        | 808 (92.4) | 558 (91.3) | 250 (95.1) |
| **Hospital admission history** |           |          |          |          |
| Admission times, n (%)  |           |          |          | 0.555    |
| 1 to 2 times            | 645 (73.8) | 455 (74.5) | 190 (72.2) |
| 3 to 6 times            | 159 (18.2) | 111 (18.2) | 48 (18.3)  |
| More than 6 times       | 70 (8.0)  | 45 (7.4)  | 25 (9.5)   |
| **Hospital stay in preceding 3 months, n (%)** | |          |          | 0.645    |
| Yes                    | 309 (35.4) | 219 (35.8) | 90 (34.2) |
| No                     | 565 (64.6) | 392 (64.2) | 173 (65.8) |
| **Previous hospitalization department** | |          |          |          |
| Medical department, n (%)| |          |          | 0.905    |
| Yes                    | 265 (30.3) | 186 (30.4) | 79 (30.0) |
| No                     | 609 (69.7) | 425 (69.6) | 184 (70.0) |
| Surgical department, n (%)| |          |          | 0.111    |
| Yes                    | 174 (19.9) | 113 (18.5) | 61 (23.2) |
| No                     | 700 (80.1) | 498 (81.5) | 202 (76.8) |
| **Intensive Care Unit (ICU), n (%)** | |          |          | 0.724    |
| Yes                    | 10 (1.1)   | 8 (1.3)   | 2 (0.8)   |
| No                     | 864 (98.9) | 603 (98.7) | 261 (99.2) |
| **Treatment history**   |           |          |          |          |
| Invasive urological procedure, n (%) | |          |          | 0.880    |
| Yes                    | 269 (30.8) | 189 (30.9) | 80 (30.4) |
| No                     | 605 (69.2) | 422 (69.1) | 183 (69.6) |
| Antibiotic use in the past 3 months, n (%) | |          |          | 0.570    |
| Yes                    | 190 (21.7) | 136 (22.3) | 54 (20.5) |
| No                     | 684 (78.3) | 475 (77.7) | 209 (79.5) |

*Independent risk factors in the training set*
The risk factor analysis was based on the 874 patients in the training set. Univariate and multivariate analysis for ESBL-PE infection is shown in Table 3. Eleven variables were identified by univariate analysis ($P < 0.1$): gender, age, immunodeficiency, urinary tract infections, severe underlying disease, hospital stay in preceding 3 months, prior admission to medical department, prior admission to surgical department, prior admission to ICU, prior invasive urological procedure, and antibiotic use in the past 3 months.

Table 3. Univariate and Multivariate analysis in the training set.
| Variables                              | Univariate |        |        |        |        |        |        |        |        |
|----------------------------------------|------------|--------|--------|--------|--------|--------|--------|--------|--------|
|                                        |            | OR     | 95% CI | P value| OR     | 95% CI | P value|        |        |
| Gender                                 |            |        |        |        |        |        |        |        |        |
| Male                                   |            | 1.654  | 1.143-2.388 | 0.0073 | 1.607  | 1.066-2.416 | 0.023 |        |        |
| Female                                 |            | Reference |        |        | Reference |        |        |        |        |
| Age                                    |            |        |        |        |        |        |        |        |        |
| 0 to 18 years                          |            | Reference |        |        | Reference |        |        |        |        |
| 18 to 60 years                         |            | 3.712  | 1.529-11.108 | 0.008  | 2.825  | 1.119-8.679 | 0.043 |        |        |
| Over 60 years                          |            | 4.765  | 2.015-14.035 | 0.001  | 4.100  | 1.678-12.343 | 0.005 |        |        |
| Diabetes mellitus                      |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 0.884  | 0.610-1.274 | 0.513 |        |        |        |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Chronic renal failure                  |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 0.886  | 0.529-1.446 | 0.637 |        |        |        |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Immunodeficiency                       |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 1.829  | 0.914-3.606 | 0.082  | 1.671  | 0.770-3.579 | 0.187 |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Neoplasia                              |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 1.444  | 0.875-2.351 | 0.143 |        |        |        |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Recurrent urinary tract infections     |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 2.181  | 1.398-3.396 | <0.001 | 1.145  | 0.645-2.011 | 0.639 |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Severe underlying disease              |            |        |        |        |        |        |        |        |        |
| Yes                                    |            | 2.294  | 1.295-4.058 | 0.004  | 1.536  | 0.805-2.907 | 0.188 |        |        |
| No                                     |            | Reference |        |        | Reference |        |        |        |        |
| Admission times                        |            |        |        |        |        |        |        |        |        |
Multivariate analysis was performed with the eleven variables identified by univariate analysis. Five variables were proved to be independent predictors for ESBL-PE infection: male gender (OR=1.607, 95% CI 1.066-2.416), older age (OR=4.100, 95% CI 1.678-12.343), a hospital stay in preceding 3 months (OR=1.872, 95% CI 1.141-3.067), invasive urological procedure (OR=1.810, 95% CI 1.197-2.729), and antibiotic use within the previous 3 months (OR 0.546, 95% CI 0.314-0.948).

**Predictive model construction and validation**

An ESBL-PE infection risk estimation nomogram model was developed by logistic regression using the five independent predictors (Figure 2). When present, each of the predictors contributes between 30 and 100 points to a final point total. This point total is then used to estimate the probability that the patient should can diagnosed as ESBL-PE positive.

The AUC was used to evaluate the discriminatory capacity of the predictive model, and the nomogram demonstrated good accuracy in estimating the risk of ESBL-PE infection. The AUC of ROC was 0.714 (95% CI, 0.671–0.757) in the training set (Figure 3A). In validation set, the AUC of ROC was 0.650 (95% CI, 0.577-0.725) (Figure 3B).

A calibration plot and Hosmer–Lemeshow test were used to the calibrate the predictive model (Figure 4). The calibration curves show the predictive model and the validation set produce very good fits of the
data. The Hosmer-Lemeshow test indicates that the predicted probability is highly consistent with the actual probability (training set, $P=0.999$; validation set, $P=0.732$). Decision curve analysis, shown in Figure 5, was used to demonstrate the net benefits of this predictive model. Its strong predictive capacity allows for accurate diagnosis, which should result in better patient treatment than either non-diagnosis or full diagnosis.

**Antibiotic susceptibility testing**

Table 4 indicates the overall antimicrobial susceptibility of PE to the antibiotics tested. The highest sensitivity was observed with amikacin (94.7%), carbapenem (95.0%), polymyxin (99.2%), tigecycline (98.9%), and latamoxef (91.2%). Except for latamoxef and cefdinir, there are statistically significant ($P<0.05$) differences in the susceptibility of all antibacterial drugs between the two groups.

Table 4. Antibiogram result of PE.
| Antibiotics   | Antibiogram result | Total | SEN | S | I | R | SEN | S | I | R | SEN | P value |
|--------------|--------------------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|---------|
|              | Non-ESBL-PE        |       |     |     |     |     |     |     |     |     |     |         |
|              | ESBL-PE            |       |     |     |     |     |     |     |     |     |     |         |
| ciprooxacin  | 304 24 265 51.3    | 39 5 220 14.8 | 857 | 40.0 | <0.001 |
| Levofloxacin | 246 66 246 44.1    | 35 18 219 12.9 | 874 | 32.2 | <0.001 |
| P/T          | 580 14 8 96.3      | 167 35 69 61.6 | 873 | 85.6 | <0.001 |
| Ceftazidime  | 540 43 16 90.2     | 26 49 196 9.6  | 870 | 65.1 | <0.001 |
| C/S          | 590 7 3 98.3       | 166 31 75 61.0 | 872 | 86.7 | <0.001 |
| Cefepime     | 533 23 45 88.7     | 18 46 207 6.6  | 872 | 63.2 | <0.001 |
| Aztreonam    | 561 1 30 94.8      | 18 2 242 6.9   | 854 | 67.8 | <0.001 |
| Amikacin     | 595 4 3 98.8       | 233 4 35 85.7  | 874 | 94.7 | <0.001 |
| Tobramycin   | 438 115 39 74.0    | 127 53 81 48.7 | 853 | 66.2 | <0.001 |
| Carbapenem   | 602 0 0 100.0      | 228 0 44 83.8  | 874 | 95.0 | <0.001 |
| TMP-SMX      | 312 1 288 51.9     | 82 0 188 30.4  | 871 | 45.2 | <0.001 |
| Polymyxin    | 600 0 2 99.7       | 267 0 5 98.2  | 874 | 99.2 | 0.033 |
| Doxycycline  | 271 123 204 45.3   | 73 43 155 26.9 | 869 | 39.6 | <0.001 |
| Minocycline  | 371 80 139 62.9    | 96 39 126 36.8 | 851 | 54.9 | <0.001 |
| Tigecycline  | 590 0 2 99.7       | 238 0 7 97.1  | 837 | 98.9 | 0.004 |
| Cefixime     | 45 0 134 25.1      | 1 0 235 0.4    | 415 | 11.1 | <0.001 |
| Latamoxef    | 53 0 2 96.4        | 50 0 8 86.2  | 113 | 91.2 | 0.095 |
| Cefdinir     | 1 0 20 4.8         | 1 0 93 1.1    | 115 | 1.7  | 0.333 |
| Ceftriaxone  | 388 0 3 99.2       | 2 0 45 4.3    | 438 | 89.0 | <0.001 |
| Cefmetazole  | 92 0 0 100.0       | 4 0 14 22.2  | 110 | 87.3 | <0.001 |
| Ceftizoxime  | 39 0 0 100.0       | 0 0 10 0.0    | 49 79.6 | <0.001 |

S: Sensitive; I: Intermediate; R: Resistant; SEN: Sensitivity, %; P/T: piperacillin/tazobactam; C/S: cefoperazone/sulbactam; TMP-SMX: trimethoprim–sulfamethoxazole

**Discussion**
UTIs are the most common class of infectious disease, and antibiotics are their main means of treatment. The most common pathogen group in urine cultures is PE, which accounts for 30% to 40% of all urine culture bacteria [9]. In recent years, ESBL-PE infection has been on the rise, and it is the main cause of hospital and community-acquired infections. In a study of antimicrobial resistance trends from 2010 to 2013, ESBL-PE was frequently detected in China and Southeast Asia, and the ESBL production rate of *E. coli* and *K. pneumoniae* in some Asian countries was as high as 60% [9]. A study by Vachvanichsanong estimated that ESBL-PE represented one-third of all *E. coli* and *K. pneumoniae* UTI episodes [11]. Data from the CHINET antimicrobial resistance monitoring project shows that the detection rate of ESBL-producing *E. coli* in China rose from 38.9% in 2005 to 55.8% in 2014, with similar rises in other countries [10].

In this study, a nomogram for predicting ESBL-PE infection from urine samples of hospitalized patients was built. This nomogram incorporated 5 predictive variables: gender, age, hospital stay in the preceding 3 months, invasive urological procedures, and antibiotic use in the past 3 months.

First, we found that older patients were significantly more likely to get ESBL-PE infections. Older age more likely to get ESBL-PE infections, which is in agreement with prior studies [27, 29]. Second, in univariate and multivariate regression analysis, gender – specifically, being male – is an independent risk factor. Many previous studies similarly consider being male a predictor of infection [19, 20]. Third, we showed that prior hospital stays were a predictor for ESBL-PE infection. This comports well with previous work which shows that hospital stays increase the risk of carrying ESBL-PE [23]. The epidemiology of these ESBL-producing bacteria is becoming more and more complicated [24]. Fourth, we included invasive urological procedures, such as intubation and catheterization, as an ESBL-PE UTI predictor, in agreement with previously published literature [26]. Invasive procedures can damage the skin and mucous membranes, thereby increasing the chance of contact with ESBL-producing bacterial strains [25]. Lastly, in this study, we found an association between the use of antibiotics in the past 3 months and the occurrence of ESBL-PE in UTI. The abuse of antibiotics in recent years has led to an increase in antibiotic resistance. ESBL-PE colonization is a known risk factor for subsequent infection or bacteremia [22]. Additionally, the improper use of antibacterial drugs has been shown to play a key role in the emergence of multi-drug resistant organisms. The selection of resistant forms may occur during or after antimicrobial treatment.

Our findings broadly agree with previous studies. Having a hospital stay in preceding 3 months, invasive urological procedures, and antibiotic use have been widely reported as the main causes of ESBL-PE infections [27, 28]. Further, comorbidities such as diabetes, chronic renal insufficiency, serious underlying diseases, and tumors were not considered predictors of UTIs caused by ESBL-PE [21], and they were found to not be significant contributors in this study either.

In addition to building a predictive model, numerous carbapenem antibiotics were tested against ESBL-PE cultures to determine whether these resistant bacteria could be combated by less-common treatments. A previous study found that there was a correlation between CTX-M-producing bacteria, one of the three
most common ESBLs genes in *E. coli* and *K. pneumoniae*, and fluoroquinolones resistance [12]. They showed that ESBL-PE had an 87.1% resistance rate to levofloxacin. It has been demonstrated that antibiotics (prophylactic or therapeutic) can induce antibiotic resistance genes that respond to ESBL-PE infection [13]. Nonstandard antibiotic treatments, such as those explored here, are therefore necessary.

We showed that carbapenems and aminoglycosides, such as amikacin, seem to be good choices for the treatment of serious infectious diseases of ESBL-PE, though they may introduce other complicating factors such as the need to closely monitor renal response. Previous studies have shown that the proportion of carbapenem-resistant PE in UTIs is less than 3% [14, 16]. However, in this study, we found that carbapenem-resistant PE could be as high as 5%, especially in the ESLB-PE group, the resistance rate of carbapenems was 16.2%.

Tigecycline and polymyxin were also demonstrated to be highly effective against ESBL-PE. Previous work has found that tigecycline has clinical effectiveness in the treatment of UTIs; however, its use is still controversial due to a lack of data and randomized controlled trials [17]. The authors recommended using tigecycline only in the absence of other potential treatments; if aminoglycosides or β-lactams can be used to treat UTI, tigecycline should be avoided. Similarly, while polymyxin is shown to be an effective treatment for UTIs, its partial conversion to colistin in the urine may induce nephrotoxicity, so it should be used with caution.

The effectiveness of piperacillin/tazobactam and cefoperazone/sulbactam against ESBL-PE were about 60%. ESBLs are generally inhibited by tazobactam [18], which could be a suitable option for initial empirical medication of ESBL-PE high-risk groups. Latamoxef showed high effectiveness against ESBL-PE, but due to the small number of subjects using the drug, further verification is needed.

This study has several limitations and ways it could be improved in the future. First, it is a retrospective case-control study with potential recall bias and selection bias. Second, some data may be missing from the medical records. Third, this study was conducted in a large hospitals in China, and only inpatients were recruited; therefore, patients may not be representative of the greater Chinese or world populations. Finally, while the sample size is sufficient for scope of this study, the logistic regression model and nomogram could be improved with an expanded dataset.

**Conclusion**

The prevalence of ESBL-PE in patients with urinary tract infections in the Chinese hospital system continues to grow, especially among men and the elderly. Hospitalization in the first 3 months, invasive urological procedures, and the use of antibiotics in the past 3 months further increase the risk of infection. The nomogram developed in this study can be used to identify high-risk patients. These patients may benefit from empirical antibiotic prescriptions, such as those explored in this study. Doing so may reduce the failure rate of treatment as promote responsible use of antibiotics which might otherwise contribute to the growing trend of antibiotic resistance.
Declarations

Acknowledgements

Not applicable.

Authors’ contributions

HL and LFX designed the study. SSQ, MHC and GCY collected and analysed the data. HL and SSQ organised the manuscript. JY and LFX reviewed the papers and revised the manuscript. All the authors (HL, SSQ, MHC, JY, GCY and LFX) have read and approved the final manuscript. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Funding information

This work was financially supported by the research project of Guangdong Provincial Bureau of traditional Chinese Medicine (No. 20201082 and No. 20191089) and Guangdong Provincial Hospital Pharmaceutical Research Fund (No.2020A27).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Conflict of interest

The authors declare that they have no competing interests.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the First Affiliated Hospital of Jinan University.

Clinical Laboratory concluded that no informed consent was required because the data are anonymized appropriately. Written informed consent was not required.

Consent for publication

Not applicable.

References
1. Mohd Sazlly Lim S, Wong PL, Sulaiman H, Atiya N, Hisham Shunmugam R, Liew SM. Clinical prediction models for ESBL-Enterobacteriaceae colonization or infection: a systematic review. The Journal of hospital infection. 2019; 102(1): 8–16.

2. Xiao Y, Hang Y, Chen Y, Fang X, Cao X, Hu X, et al. A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Chinese Tertiary Hospital. Infect Drug Resist. 2020; 13: 4289–96.

3. Martinez-Valencia AJ, Gomez MB, Montanez AA, Garcia K, Sanchez PR, Jimenez CL, et al. Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections. Bmc Infect Dis. 2020; 20(1): 558.

4. Kim M, Song KH, Kim CJ, Choe PG, Park WB, Bang JH, et al. Clinical Prediction Score for Community-Onset Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella Species. J Korean Med Sci. 2019; 34(14): e116.

5. Shigemura K, Kitagawa K, Osawa K, Yamamichi F, Tokimatsu I, Nomi M, et al. Comparison of antibiotics use, urinary tract infection (UTI)-causative bacteria and their antibiotic susceptibilities among 4 hospitals with different backgrounds and regions in Japan. J Chemother. 2018; 30(1): 31–6.

6. Lee H, Han SB, Kim JH, Kang S, Durey A. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department. The American journal of emergency medicine. 2018; 36(9): 1608–12.

7. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014; 20 Suppl 1: 1–55.

8. Xie J, Peters BM, Li B, Li L, Yu G, Xu Z, et al. Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001–2015. Microb Pathogenesis. 2017; 107: 206–11.

9. Yi-Te C, Shigemura K, Nishimoto K, Yamada N, Kitagawa K, Sung SY, et al. Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. J Int Med Res. 2020; 48(2): 1219667378.

10. Xiao T, Wu Z, Shi Q, Zhang X, Zhou Y, Yu X, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. Journal of global antimicrobial resistance. 2019; 17: 147–56.

11. Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect. 2020; 149: e12.

12. Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016; 22 Suppl 1: S9-14.

13. Tenney J, Hudson N, Alnifaidy H, Li J, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Saudi Pharm J. 2018; 26(5):
14. Gomila A, Shaw E, Carratala J, Leibovici L, Tebe C, Wiegand I, et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrob Resist Infect Control. 2018; 7: 111.

15. Lee H, Han SB, Kim JH, Kang S, Durey A. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department. The American journal of emergency medicine. 2018; 36(9): 1608–12.

16. Goossens H, MYSTIC SGE. MYSTIC program: summary of European data from 1997 to 2000. Diagn Micr Infec Dis. 2001; 41(4): 183–9.

17. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016; 34(7): 1031–7.

18. Albaramki JH, Abdelghani T, Dalaeen A, Khdair AF, Alassaf A, Odeh R, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr Int. 2019; 61(11): 1127–32.

19. Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study. Bmc Infect Dis. 2017; 17(1): 138.

20. Boyer A, Couallier V, Clouzeau B, Lasheras A, M'Zali F, Kann M, et al. Control of extended-spectrum beta-lactamase-producing Enterobacteriaceae nosocomial acquisition in an intensive care unit: A time series regression analysis. Am J Infect Control. 2015; 43(12): 1296–301.

21. Golzarri MF, Silva-Sanchez J, Cornejo-Juarez P, Barrios-Camacho H, Chora-Hernandez LD, Velazquez-Acosta C, et al. Colonization by fecal extended-spectrum beta-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control. 2019; 47(8): 916–21.

22. Vock I, Aguilar-Bultet L, Egli A, Tamma PD, Tschudin-Sutter S. Independent, external validation of clinical prediction rules for the identification of extended-spectrum beta-lactamase-producing Enterobacteriales, University Hospital Basel, Switzerland, January 2010 to December 2016. Euro Surveill. 2020; 25(26).

23. Garcia-Tello A, Gimbernat H, Redondo C, Meilan E, Arana DM, Cacho J, et al. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram. Scand J Urol. 2018; 52(1): 70–5.

24. Liao K, Chen Y, Wang M, Guo P, Yang Q, Ni Y, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae causing intra-abdominal infections from 9 tertiary hospitals in China. Diagn Microbiol Infect Dis. 2017; 87(1): 45–8.

25. Espinar MJ, Miranda IM, Costa-de-Oliveira S, Rocha R, Rodrigues AG, Pina-Vaz C. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-
26. Kwon KT, Kim B, Ryu S, Wie S, Kim J, Jo H, et al. Changes in Clinical Characteristics of Community-Acquired Acute Pyelonephritis and Antimicrobial Resistance of Uropathogenic Escherichia coli in South Korea in the Past Decade. Antibiotics (Basel). 2020; 9(9): 1.

27. Yu Y, Shen H, Zhu C, Guo R, Gao Y, Lu L. Infections Caused by Extended-Spectrum beta-Lactamase Producing Escherichia Coli in Systemic Lupus Erythematosus Patients: Prevalence, Risk Factors, and Predictive Model. Biomed Res Int. 2018; 2018: 8296720.

28. Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). Journal of chemotherapy (Florence). 2014; 26(3): 133–8.

29. Wu G, Abraham T, Saad N. Role of Tigecycline for the Treatment of Urinary Tract Infections. Journal of Pharmacy Technology. 2014; 30(3): 87–92.

30. Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study. Bmc Infect Dis. 2017; 17(1): 138.

Figures
Figure 1

Experimental flowchart.
Figure 2

A nomogram for predicting the probability of ESBL-producing pathogen infection. Each variable is scored vertically against the Points scale at the top of the nomogram. The scores for all variables are then summed to obtain the patient’s Total Points, which are compared vertically against the corresponding Diagnostic possibility scale to estimate the probability of ESBL-producing pathogen infection.
Figure 3

ROC curves form the training (A) and validation set (B) with AUC and 95% CI.
Figure 4

Calibration plots. The shadow line represents perfect prediction by an ideal model. The solid line shows the model's performance using the training set (A) and validation set (B), with Hosmer–Lemeshow test P values of 0.999 and 0.732, respectively. The dotted line represents the predictive performance by a nonparametric model using the training set (A) and validation set (B).

![Calibration plots](image)

Figure 5

Decision curve analysis of the training set (A) and validation set (B). The black solid line indicates that no patients were treated. The grey solid line indicates that all patients were treated. The dotted line indicates treatment according to the model. The area between the dotted line, the grey solid line, and the black solid line represents the net benefit accrued by utilizing the model.

![Decision curve analysis](image)